Chimerix, Inc. (CMRX)
CMRX Stock Price Chart
Key Info
| Market Cap | 226.73M |
| Revenue (ttm) | 11.02M |
| Net Income (ttm) | -35.35M |
| Shares Out | 62.24M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $3.62 |
| Previous Close | $3.44 |
| Change ($) | 0.18 |
| Change (%) | 5.23% |
| Day's Open | 3.47 |
| Day's Range | 3.41 - 3.63 |
| Day's Volume | 239,815 |
| 52-Week Range | 1.27 - 3.81 |
CMRX Stock News
Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript
DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious disea...
DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious disea...
DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious di...
Chimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2020 Results - Earnings Call Transcript
Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Chimerix (NASDAQ:CMRX) were flat in pre-market trading after the company reported Q2 results.
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious dis...
Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise
Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.
Chimerix (CMRX) delivered earnings and revenue surprises of -13.33% and -17.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Chimerix (NASDAQ:CMRX) were unchanged at $2.52 after the company reported Q1 results.
FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study
DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious di...
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Chimerix, Inc. (CMRX) CEO Mike Sherman on Q4 2019 Results - Earnings Call Transcript
Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection Brincidofovir demonstrated a statistically s...
Is (CMRX) Outperforming Other Medical Stocks This Year?
DURHAM, N.C., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other seri...
Chimerix's (CMRX) CEO Michael Sherman on Q3 2019 Results - Earnings Call Transcript
Includes All Human Indications Excluding Prevention and Treatment of Smallpox
Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor Chimerix.
Chimerix's (CMRX) CEO Mark Iwicki on Q1 2019 Results - Earnings Call Transcript
Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and 17.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News of changes to its executive team boosted Chimerix Inc. shares on Tuesday. Specifically, the firm announced the appointment of Michael A. Sherman as chief executive of Chimerix, effective ...
About CMRX
Chimerix, a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic ste... [Read more...]
| Industry Biotechnology | IPO Date Apr 11, 2013 |
| CEO Michael Sherman | Employees 43 |
| Stock Exchange NASDAQ | Ticker Symbol CMRX |
Financial Performance
In 2019, Chimerix's revenue was $12.52 million, an increase of 73.49% compared to the previous year's $7.22 million. Losses were -$112.58 million, 62.0% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for Chimerix is 6.67, which is an increase of 84.25% from the latest price.